
|Articles|June 15, 2003
InSite Vision starts study of ISV-403 treatment
Alameda, CA-InSite Vision Inc. has initiated a phase I clinical study with ISV-403, a treatment for ocular bacterial infections.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Evolving glaucoma therapy: A new era of interventional strategies
2
ICYMI: AAO 2025 showcases new technologies and continued research
3
Precision strategy: Optimizing visual outcomes with advanced small-aperture lenses
4
Throwback Series: Managing bilateral diabetic macular edema early in practice
5

















































.png)


